ModifiedPremera BluecrossPolicy 7.01.84

Hearing Aids (including semi- and fully-implantable middle ear devices)

Defines coverage stance and clinical considerations for semi-implantable and fully implantable middle ear hearing aids and references coding, clinical evidence, and state-specific mandate language. Affects providers submitting coverage requests for these devices under Premera Blue Cross.

Policy Summary

PayerPremera Bluecross

PolicyHearing Aids (including semi- and fully-implantable middle ear devices)

Policy CodePolicy 7.01.84

Change TypeMaterial updates: CPT additions, minors criteria, WA mandate

Effective DateJan 1, 2026

Next Review DateJan 1, 2026

Key ActionObtain and document prior authorization when required, including device-specific selection criteria and FDA product codes, before submitting coverage requests.

SourceLink

POLICY UPDATE CHANGES

Added coverage criteria for minors under 18 years of age.

Added new CPT codes 0951T–0955T in the Q3 coding update.

Benefit Application updated to include new Washington (WA) mandate effective January 1, 2026.

5CPT codes added

2Semi-implantable FDA devices

1Fully implantable FDA devices

36 monthsWA coverage frequency (per ear)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Age indicated per FDA labeling

Minors criteria addedAge applicability updated

Coverage Criteria and Medical Necessity

Investigational - Semi- and Fully-Implantable Middle Ear Hearing Aids

Investigational designation: Semi-implantable and fully implantable middle ear hearing aids are considered investigational due to insufficient evidence to determine safety and effectiveness compared with external acoustic hearing aids.

Policy states investigational for middle ear hearing aids; limited small studies and short follow-up limit conclusions

Device selection considerations (referenced)

Device-specific selection characteristics (for reference; not coverage-approving criteria in this part of document)

Vibrant Soundbridge selection: Pure-tone air-conduction thresholds within device-specific limits (see Table 1 in device labeling); word recognition score >= 50% using recorded material; normal middle ear anatomy and tympanic membrane; normally functioning Eustachian tube; psychologically and motivationally suitable with realistic expectations; minimum 30 days experience with appropriately fitted hearing aids.

Listed in Vibrant Soundbridge package insert; provided for reference

Maxum System selection: Intended for adults >=18 years with moderate-to-severe sensorineural hearing loss who desire an alternative to an acoustic hearing aid; recommended prior experience with appropriately fitted hearing aids.

Device labeling referenced (Maxum System)

Esteem selection: Adults >=18 years; stable bilateral sensorineural hearing loss with pure-tone average moderate (40-70 dB) to severe (71-90 dB); unaided speech discrimination >= 40%; adequate anatomic space for implant verified by high-resolution CT; minimum 30 days experience with appropriately fitted hearing aids.

Esteem device labeling referenced

General medical necessity

Covered when ALL of the following are met:

General coverage conditions

Clinical justification: Hearing aids are medically inappropriate or cannot be utilized due to congenital malformations, chronic disease, severe sensorineural hearing loss, or surgery.
Medicare Benefit Policy Manual language
Device approval: Device has FDA premarket approval for the intended indication (examples: Vibrant Soundbridge MPV; Esteem OAF).
FDA regulatory status and product codes

Prior trial and documentation (reference): Prior experience with appropriately fitted external hearing aids and device-specific selection documentation (pure-tone thresholds, word recognition / speech discrimination scores, normal middle ear anatomy, imaging when indicated) should be documented.

Documentation and prior trial recommended per device labeling and policy; prior authorization may be required by contract/state mandates

External acoustic hearing aids are the established, lower-risk first-line treatment for most cases of sensorineural hearing loss. Semi‑implantable and fully‑implantable middle ear hearing aids are positioned in the policy as alternative options when an external acoustic hearing aid is not appropriate or does not provide adequate benefit. These implantable devices detect sound and transduce signals directly to the ossicles in the middle ear, and therefore are considered only when the potential additional hearing benefit justifies the surgical risks compared with conventional external amplification.

Medicare’s Benefit Policy Manual excludes routine coverage of conventional hearing aids. The manual explains that devices that replace the function of the middle ear, cochlea, or auditory nerve may be payable as prosthetic devices only when hearing aids are medically inappropriate or cannot be utilized (for example because of congenital malformations, chronic disease, severe sensorineural hearing loss, or prior surgery). Semi‑ and fully‑implantable middle ear hearing aids are not specifically listed in the manual and therefore may have different coverage implications depending on whether they are considered prosthetic replacements in a given case.

The policy designates semi‑implantable and fully‑implantable middle ear hearing aids as investigational because the current evidence is insufficient to determine net health benefit compared with external acoustic hearing aids. Although single‑arm studies and observational series suggest some individuals may experience improved hearing outcomes, studies to date are limited in size and duration (median follow‑up under five years), and the incremental benefit must clearly outweigh the risks of surgical implantation.

Devices that do not have FDA premarket approval or clearance are considered investigational within this policy. For example, the Carina fully implantable hearing device was in development and had conducted early‑phase trials under IDEs but did not have FDA approval at the time of the document; such devices lack the regulatory evidence base required for routine coverage.

Coding and Diagnostic Details

CPT (Totally implantable middle ear hearing implant codes)CPT

0951T	Totally implantable active middle ear hearing implant; initial placement, including mastoidectomy, placement of and attachment to sound processor (new code effective 07/01/25)
0952T	Totally implantable active middle ear hearing implant; revision or replacement, with mastoidectomy and replacement of sound processor (new code effective 07/01/25)
0953T	Totally implantable active middle ear hearing implant; revision or replacement, without mastoidectomy and replacement of sound processor (new code effective 07/01/25)
0954T	Totally implantable active middle ear hearing implant; replacement of sound processor only, with attachment to existing transducers (new code effective 07/01/25)
0955T	Totally implantable active middle ear hearing implant; removal, including removal of sound processor and all implant components (new code effective 07/01/25)

HCPCSHCPCS

S2230	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear
V5095	Semi-implantable middle ear hearing prosthesis

Updated CPT codesCPT

0951T	newly added CPT (Q3 coding update)
0952T	newly added CPT (Q3 coding update)
0953T	newly added CPT (Q3 coding update)
0954T	newly added CPT (Q3 coding update)
0955T	newly added CPT (Q3 coding update)

FDA product codesmixed

MPV	FDA product code for Vibrant Soundbridge
OAF	FDA product code for Esteem

inv-12: Word recognition score — selection threshold

Selection threshold>= 50% word recognition score (recorded material) per Vibrant Soundbridge package insert

Test methodWord recognition using recorded material as specified in device labeling

ContextListed as a device-specific selection criterion (reference only; not coverage-approving)

inv-13: Unaided speech discrimination (Esteem) — threshold

Selection threshold>= 40% unaided speech discrimination test score per Esteem labeling

Age requirement

Provider Requirements and Billing Actions

Prior Authorization

Prior Authorization / Benefit Verification

Prior authorization may be required by the member's contract or state mandate. Verify benefits and obtain any required prior authorization before scheduling services; authorization requirements may vary by employer group, funding type (fully insured vs self-funded), and state law.

Prior authorization depends on member-specific contract and may be required under Washington mandate for plans issued/renewed on/after 2026-01-01.
Self-funded groups may not be subject to state mandates — check the member contract.

Billing Rule

Coding Update — CPT 0951T–0955T

Addition of CPT codes 0951T–0955T in the 2025 Q3 coding update may affect billing and prior authorization workflows. Confirm applicable codes on authorizations and claims submissions.

Background and Context

Semi‑implantable and fully‑implantable middle ear hearing aids are implantable alternatives to external acoustic hearing aids that work by detecting sound and directly stimulating the middle ear structures. Semi‑implantable systems typically couple an implanted magnetic or mechanical component to the ossicles with an external processor, while fully‑implantable systems contain all components beneath the skin and may use piezoelectric transduction. These devices are intended for individuals who cannot obtain sufficient benefit from or cannot use conventional external hearing aids, but available evidence is limited and long‑term outcomes and comparative effectiveness versus other implantable options remain uncertain.

Definitions and Device Summaries

inv-23: Degree of hearing loss definitions

Mild20–40 dB pure-tone average

Moderate40–60 dB pure-tone average

Severe60–80 dB pure-tone average

Profound≥ 80 dB pure-tone average

inv-24: Device types and transduction

Semi-implantable devicesImplanted magnetic component attached to ossicles with an external sound processor/receiver (electromagnetic transduction)

Fully implantable devicesAll components implanted (sensor, processor, driver) using piezoelectric transduction with no external processor

Revision History and Material Changes

2025-10-01coding_update

Added new CPT codes 0951T–0955T as part of the Q3 coding update to align coding with policy criteria.

2025-09-09interim_review_effective_date

Interim review approved; changes effective for dates of service on or after 2026-01-01 following 90-day provider notification.

2025-09-09coverage_criteria_added

Added coverage criteria for minors under 18 years of age.

Policy Summary

PayerPremera Bluecross

PolicyHearing Aids (including semi- and fully-implantable middle ear devices)

Policy CodePolicy 7.01.84

Change TypeMaterial updates: CPT additions, minors criteria, WA mandate

Effective DateJan 1, 2026

Next Review DateJan 1, 2026

Key ActionObtain and document prior authorization when required, including device-specific selection criteria and FDA product codes, before submitting coverage requests.

SourceLink

On This Page

Device labeling specifies use in individuals 18 years of age or older

ContextListed as a device-specific selection criterion (reference only; not coverage-approving)

New CPT codes: 0951T, 0952T, 0953T, 0954T, 0955T (effective for dates of service on or after 2026-01-01 per coding update).
Update internal billing systems and authorization templates to include these codes.

Documentation Required

Prior Trial of External Hearing Aids

Members should generally have experience with appropriately fitted external (acoustic) hearing aids prior to consideration of semi- or fully‑implantable middle ear hearing devices. Document prior trial duration and outcomes in the medical record.

Minimum documented trial: typically ≥30 days of experience with appropriately fitted hearing aids for devices like Vibrant Soundbridge/Esteem.
Document hearing aid make/model, fitting verification, and patient-reported benefits/limitations.

Documentation Required

Device Selection Documentation

Document device selection rationale and relevant clinical criteria in the record to support medical necessity determinations.

Pure‑tone air‑conduction thresholds and word recognition scores (e.g., Vibrant Soundbridge criteria: word recognition ≥50%).
Anatomy and imaging: normal middle ear anatomy, adequate space on high‑resolution CT when indicated.
Patient factors: psychological suitability, realistic expectations, and reason for preferring implantable device over external aids.

Documentation Required

FDA Labeling and Product Codes

Maintain and include FDA labeling, age indications, and product codes in the clinical documentation for the implanted device.

FDA labeling: devices approved for adults ≥18 years (Vibrant Soundbridge, Maxum, Esteem).
FDA product codes: MPV (semi‑implantable devices) and OAF (Esteem).
If the device lacks FDA approval (investigational devices), clearly document investigational status and that the device is not FDA‑approved.

Denial Risk

Investigational Designation — Denial Risk

Devices or indications designated investigational are subject to denial. Do not submit claims for investigational devices expecting coverage unless explicit authorization is obtained and the device is covered under the member's contract.

Semi‑ and fully‑implantable middle ear hearing aids considered investigational for certain indications (see policy coverage criteria).
Devices without FDA approval (e.g., Carina in development) are investigational and typically not covered.

Note

Medicare Coverage Note

Medicare excludes routine hearing aids from coverage; however, devices that replace middle ear, cochlea, or auditory nerve function may be considered prosthetic and payable when hearing aids are medically inappropriate.

Medicare Benefit Policy Manual: hearing aids excluded; replacement/prosthetic devices may be payable when appropriate.
Coverage determination for semi‑/fully‑implantable devices under Medicare is not explicitly defined — verify Medicare contractor policy and document medical necessity if pursuing coverage.

Processor placement examplesSemi-implantable: processor worn externally over subcutaneous receiver (Soundbridge) or rests over external ear canal (Maxum)

inv-25: Semi-implantable active middle ear implant (Vibrant Soundbridge) — FDA product code MPV; adult indication summary

DeviceVibrant Soundbridge (semi-implantable active middle ear implant)

FDA product codeMPV

Indication summaryIntended for use in adults 18 years or older with moderate to severe sensorineural hearing loss who desire an alternative to an acoustic hearing aid; selection includes pure-tone thresholds within device limits, normal middle ear anatomy, and >=50% word recognition score (recorded material)

inv-26: Fully implantable middle ear hearing aid (Esteem Implantable Hearing System) — FDA product code OAF; adult indication summary

DeviceEsteem Implantable Hearing System (fully implantable middle ear hearing aid)

FDA product codeOAF

Indication summaryIntended to alleviate hearing loss in adults 18 years or older with stable bilateral sensorineural hearing loss; selection includes moderate to severe pure-tone average (40–90 dB range described across labels) and unaided speech discrimination >=40%

2025-09-09benefit_application_updateLatest

Benefit application updated to include new Washington (WA) mandate effective 2026-01-01.